1upHealth Launches Prior Authorization Solution and Technology Partnerships to Support CMS Electronic Prior Authorization Mandate for Health Plans

Ochre Bio appoints ex- Eli Lilly and AstraZeneca VP as Non-Executive Director

The appointment and ongoing science team expansion will help the company advance late-stage liver disease therapeutics

Latest Nature Communications Study: AI-Enabled Development of Next-Generation ENPP1 Inhibitors for Innate Immune Modulation by Insilico Medicine

Publication showcases the capabilities of Insilico's advanced generative AI platform and integrated workflow in facilitating the rapid development of ISM5939, further demonstrating the potential of AI in drug discovery. Unlike direct STING agonists, ISM5939 precisely modulates the STING pathway within tumor tissues by targeting ENPP1, thereby restoring local immune activation and enhancing anti-tumor immune responses. For the first time, ENPP1 inhibitors have been shown to overcome dual resistance to immune checkpoint inhibitors and chemotherapy, offering a new therapeutic hope for patients with refractory tumors. Since the start of 2025, this marks Insilico Medicine’s third AI-driven drug discovery study published in a Nature sub-journal. Immune checkpoint inhibitors have transformed cancer treatment, providing clinical benefits for a wide range of malignancies. However, only ~10-35% of patients on these treatments achieve a meaningful and durable response, underscoring the urgent need for innovative therapeutic strategies.

Ambience Healthcare's AI Platform Surpasses Clinician Performance by 27% in Medical Coding, Powered by New OpenAI Breakthrough

Association for Molecular Pathology Releases Series of Reports Defining Core Bioinformatics Competencies for Clinical Diagnostic Laboratories

AMP announced the release of a three-part series of papers on core bioinformatics capabilities for professionals in clinical molecular diagnostic labs.

Nuclera and Cytiva collaborate to accelerate characterization of proteins for drug development

● Collaboration combines Nuclera’s eProtein Discovery System, which accelerates protein expression, purification and optimization, with Cytiva’s Biacore SPR system, which characterizes molecular interactions ● Collaboration allows researchers to progress rapidly from DNA to purified and characterized protein, to facilitate insights into drug-target interactions ● Showcased at Discovery on Target and PEGS Europe conferences, detailing the production and characterization of Bruton’s Tyrosine Kinase, which is implicated in B-cell malignancies

Sapio Sciences Appoints Gordon McCall as Chief Operating Officer to Drive Global Operational Excellence

Sapio Sciences, the science-aware™ lab informatics platform, today announced the promotion of Gordon McCall to Chief Operating Officer (COO). McCall has served as the company’s Chief Financial Officer (CFO) since 2022 and brings a proven track record of leadership, strategic execution, and operational acumen.

START and OneOncology Partner To Expand Access to Early Phase Oncology Trials

This partnership will launch three new START research sites to bring early phase trials closer to patients in major U.S. communities.

Neurogen Biomarking Announces Partnership with Aranscia

Pythia Biosciences and Miraomics to Build a High-Quality Single-Cell Database for Drug Research and AI/ML Acceleration

Pythia Biosciences and Miraomics today announced their collaboration to develop Pythiomics—a rich, high-quality and harmonized single-cell omics database designed to accelerate discoveries and AI/ML development in drug research.

4D Path Expands Scientific Advisory Board with Global Leaders in Oncology and Pathology

4D Path, a company dedicated to personalizing cancer care through its unprecedented approach to predicting tumor response, recently convened its Scientific Advisory Board (SAB), bringing together an exceptional group of oncology, pathology, and translational research leaders, each deeply committed to advancing precision oncology and translating innovation into patient impact.

Astoriom Expands Global Footprint for Sample Stability Storage Services

Growth in dedicated sample stability facilities at Tramore (Ireland) site to meet demand for flexible, regulatory-compliant storage solutions

Onvida Health and Ambience Healthcare Partner to Enhance Patient Care and Revolutionize Clinical Workflows with AI Technology

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate strategic update.

Abzena Announces Establishment of Scientific Advisory Board to Support Innovation Strategy

Zymo Research to Host BioFestival at Johns Hopkins University, Empowering Scientific Innovation and Sustainability

My name is Nora Beik, and I am reaching out from Zymo Research to share our latest press release announcing the upcoming BioFestival at Johns Hopkins University, a campus event dedicated to accelerating innovation, celebrating sustainability, and supporting early-career researchers. BioFestival is a growing initiative led by Zymo Research in partnership with top-tier academic institutions, with the goal of empowering the next generation of scientists. This latest installment—hosted in collaboration with Johns Hopkins University—highlights Zymo Research’s ongoing commitment to serving as a trusted partner to academia and a leader in sample preparation for life sciences. We invite you to read the full press release here: https://www.zymoresearch.com/blogs/press-releases/biofestival-johns-hopkins-university We would greatly appreciate it if you would consider sharing this news with your readers. If you require any additional information, high-resolution images, or would like to arrange an interview with one of our experts, please do not hesitate to reach out. I look forward to the opportunity to collaborate with your team. Thank you for your time and consideration.

eClinical Solutions Welcomes Sean Lannan as Chief Financial Officer

Lannan and new Board of Directors member Jason Blessing will help propel the company’s next phase of growth

START Doses First U.S. Patient in Moderna’s Phase 1 Clinical Trial of mRNA-4106, a Pan-Tumor Antigen Therapy Candidate, in Solid Tumors

This major study milestone highlights START’s commitment to bringing novel cancer therapies to patients through community-based early-phase clinical trials.

Inizio Evoke Supercharges Creative Leadership with Dual ECD Appointments

CapeStart Helps Life Science Teams Scale Faster, Boost Productivity with New Release of MadeAi™, Award-Winning GenAI Platform

CapeStart announced a major new release of MadeAi™, its GenAI-based platform whose enhancements also power the MadeAi-LR solution for systematic literature review (SLR). MadeAi helps time-strapped teams to advance the pace of scientific research by cutting literature review time in half and delivering 90% accuracy.